<DOC>
	<DOCNO>NCT02023593</DOCNO>
	<brief_summary>This phase Ⅱ study design evaluate efficacy safety FOLFIRI second-line treatment metastatic esophageal carcinoma .</brief_summary>
	<brief_title>FOLFIRI Second Line Chemotherapy Metastatic Esophageal Carcinoma</brief_title>
	<detailed_description>Although standard second-line treatment metastatic esophageal carcinoma , study show irinotecan , fluorouracil may effective treat patient metastatic esophageal carcinoma failure first-line treatment . Since irinotecan , fluorouracil , leucovorin work different way stop growth tumor . Giving one drug may effective . In phase Ⅱ trial , investigator would like observe efficacy safety FOLFIRI ( Irinotecan/5-FU/leucovorin ) second-line treatment metastatic esophageal carcinoma .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Patients provide sign Informed Consent Form Karnofsky score ≥70 Age : 1875 year old Histologically confirm diagnosis advance esophageal carcinoma Patients Received progressed firstline treatment , receive CPT11 Fluoropyrimidine base palliative chemotherapy Measurable disease least 1 diameter CT scan MRI per RECIST 1.1 criterion Life expectancy ≥ 3 month Patient adequate bone marrow organ function Absolute Neutrophil Count ( ANC ) ≥ 1.5 x 109/L Platelets ≥ 75 x 109/L Hemoglobin ≥ 9.0 g/dL Patient adequate liver function AST ALT 2.5 time ULN ( 5.0 time ULN liver metastasis ) Serum bilirubin ≤ 2 x ULN Creatinine ≤ 1.5 time ULN Good compliance Pregnant lactate woman Brain metastasis bone metastasis . Patients severe infection active peptic ulcer need treatment Severe systemic disease control unstable uncompensated respiratory , cardiac , liver , renal disease Patient concurrent malignancy malignancy within 5 year study enrollment , ( exception nonmelanoma skin cancer cervical carcinoma situ Psychiatric illness would prevent patient give informed consent Patient concurrently use approve investigational antineoplastic agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>